This study highlights the high rate of 0% target trough concentration attainment per treatment course in our centers and identifies patients with residual diuresis and/or early stages of treatment (less than 7 days) as populations that may benefit from closer vancomycin TDM.
Nguyen et al. (Thu,) studied this question.